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Abstract
Acute hyperglycaemia has been associated with complications,
prolonged intensive care unit and hospital stay, and increased
mortality. We made an inventory of the prevalence and prognostic
value of hyperglycaemia, and of the effects of glucose control in
different groups of critically ill patients. The prevalence of
hyperglycaemia in critically ill patients, using stringent criteria,
approaches 100%. An unambiguous negative correlation between
hyperglycaemia and mortality has been described in various
groups of critically ill patients. Although the available evidence
remains inconsistent, there appears to be a favourable effect of
glucose regulation. This effect on morbidity and mortality depends
on patient characteristics. To be able to compare results of future
studies involving glucose regulation, better definitions of
hyperglycaemia (and consequently of normoglycaemia) and patient
populations are needed.
Introduction
Acute hyperglycaemia is frequently present in situations of
stress, both in diabetic and in nondiabetic patients [1-3].
Because it is so common, it could be viewed as a physiologic
adaptation during the ‘fight or flight’ response. On the other
hand, it has been associated with complications, prolonged
intensive care unit (ICU) and hospital stay, and increased
mortality. The important issue is whether hyperglycaemia is
just related to disease severity or is an independent risk
factor that contributes to morbidity and mortality [4]. If
hyperglycaemia is an independent risk factor, then tight
glucose control (TGC) may have beneficial effects on
morbidity and mortality. Conversely, if hyperglycaemia is not a
risk factor per se, then the risks associated with glucose
control may outweigh the benefits. We made an inventory of
the prevalence and prognostic value of hyperglycaemia, and
of the effects of glucose control in different groups of critically
ill patients, in order to evaluate the available evidence.
Prevalence and prognostic value of
hyperglycaemia
Table 1 provides an overview of various situations in which a
correlation between hyperglycaemia and mortality has been
demonstrated. Different authors use different threshold
values to define hyperglycaemia.
General hospital patients
Among patients admitted to a general hospital, 38%
exhibited increased blood glucose (BG) values, defined as
either fasting BG values above 7 mmol/l or two random
values above 11.1 mmol/l [5]. In that retrospective study 16%
of 223 patients admitted with new onset hyperglycaemia
(without a history of diabetes mellitus) died during their stay
in hospital, as compared with only 1.7% of 1168 patients
without hyperglycaemia (P < 0.001). The cause of death in
the hyperglycaemia group was more often related to infection
(33% versus 20% without hyperglycaemia) or acute neuro-
logical complications (19% versus 10%). Patients with new
onset hyperglycaemia had a longer hospital stay and were
more often admitted to the ICU (29% versus 9%). In this
study, diabetic patients had a better prognosis than newly
hyperglycaemic patients.
Intensive care unit patients
In one study conducted in medical ICU patients [6],
admission BG was above 11.1 mmol/l in 23%. In another
study [7], conducted in thoracosurgical ICU patients,
admission glucose was above 6.1 mmol/l in 86% and almost
Review
Hyperglycaemia in critically ill patients: marker or mediator of
mortality?
Anouk M Corstjens1, Iwan CC van der Horst2, Jan G Zijlstra3, AB Johan Groeneveld4, 
Felix Zijlstra2, Jaap E Tulleken3 and Jack JM Ligtenberg3
1Department of Anaesthesiology, Intensive & Respiratory Care Unit, University Medical Center Groningen, Groningen, The Netherlands
2Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands
3Intensive & Respiratory Care Unit, University Medical Center Groningen, Groningen, The Netherlands
4Department of Intensive Care, Vrije Universiteit Medical Center, Amsterdam, The Netherlands
Corresponding author: Jack JM Ligtenberg, j.j.m.ligtenberg@int.umcg.nl
Published: 27 June 2006 Critical Care 2006, 10:216 (doi:10.1186/cc4957)
This article is online at http://ccforum.com/content/10/3/216
© 2006 BioMed Central Ltd
AMI = acute myocardial infarction; BG = blood glucose; CVA = cerebrovascular accident; GIK = glucose–insulin–potassium; ICU = intensive care
unit; TGC = tight glucose control.
Page 2 of 5
(page number not for citation purposes)
Critical Care    Vol 10 No 3 Corstjens et al.
all patients (96%) became hyperglycaemic during their ICU
stay. Freire and coworkers [8] reported a mean admission
glucose of 7.8 mmol in 1185 mixed ICU patients. In a study
conducted in nearly 5000 ICU patients, Egi and colleagues
[9] recently found a mean glucose of 8.2 mmol/l. In mixed
ICU patients with a mortality of 15%, BG during admission
was above 11.1 mmol/l in 54%; all patients had BG levels
above 6.1 mmol/l during their ICU stay [10]. Hyperglycaemia
was a risk factor for increased morbidity and mortality in
critically ill surgical patients (n = 97) but not in medical
patients (n = 38). However, the number of medical patients
was relatively small, and so no firm conclusions can be
drawn. In various ICU populations, the association between
hyperglycaemia and in-hospital mortality was not uniform;
hyperglycaemia was an independent risk factor only in
patients without a history of diabetes in the cardiac,
cardiothoracic and neurosurgical ICUs [11]. A retrospective
study conducted in a mixed ICU population of 1826 patients
[12] showed that even a modest degree of hyperglycaemia
was associated with an increase in hospital mortality;
admission BG as well as mean BG were higher in
nonsurvivors than in survivors. However, in another
retrospective study [4], conducted in 1085 consecutive
mixed ICU patients (ICU mortality 20%), hyperglycaemia was
not an independent risk factor for mortality in a multivariate
model (Fig. 2).
Patients with acute myocardial infarction
In a study of 336 patients with acute myocardial infarction
(AMI) [13], the admission BG value in 15% was 11.1 mmol or
greater; more than 40% of these patients with a BG value of
11.1 mmol/l or more on admission died within 1 year, as
compared with approximately 10% of patients with normal or
slightly elevated BG values. In a prospective study of 305
patients with AMI [14] one out of four patients appeared to
have diabetes mellitus, with an admission BG of 17.1 mmol/l.
In a meta-analysis of 1856 AMI patients [15] patients without
known diabetes mellitus but with BG values above 6.1 mmol/l
had a fourfold increased chance of dying compared with
patients with lower BG values. In diabetic patients with
elevated BG values (> 8.0 mmol/l), mortality risk was nearly
doubled. In another study [16], conducted in 846 AMI
patients, admission BG level appeared to be an independent
predictor of long-term mortality in patients with and in those
without known diabetes. In that study, patients were stratified
according to their level of hyperglycaemia, and a clear
correlation between level of hyperglycaemia and increased
risk for mortality was identified (Figure 1). In the DIGAMI
(Diabetes Insulin-Glucose in Acute Myocardial Infarction) 2
study [17] glucose level was a strong and independent
predictor of long-term mortality in diabetic patients with AMI.
Patients with cerebrovascular accident
In a study of 656 patients with an established cerebro-
vascular accident (CVA) [18], 25% had a BG above
10.0 mmol/l. In that retrospective study acute hyperglycaemia
predicted increased mortality after 1 year; 18% of 258
patients with a BG of 7.2 mmol/l or more had died compared
with 11% of 385 patients with a BG below 7.2 mmol/l. In
another study conducted in CVA patients without known
diabetes mellitus but with elevated BG values (> 6.1 mmol/l)
[19], the risk for dying within 30 days was threefold.
Trauma patients
In a prospective study conducted in 738 trauma patients [2],
‘moderate’ hyperglycaemia (BG > 11.1 mmol/l) but also ‘mild’
Table 1
Prognostic value of hyperglycaemia
Hyperglycaemia Mortality 
Stress situation Patients (n) (definition [mmol/l]) (high versus lower BG)
Acute hospital admission [5] 1886 fasting > 7, twice > 11.1 16% versus 1.7%
Surgical intensive care patients [10] 97 ≥6.1 32% versus 8%
Trauma [2] 738 > 11.1 34.1% versus 3.7%
Trauma [20] 1003 > 11.1 RR 2.2-fold higher
Severe burn injury [38] 58 > 7.8 27% versus 4%
Acute myocardial infarction [15] 1856 ≥6.1 RR 4-fold higher
Myocardial infarction in diabetic patients [15] 688 ≥10 RR 1.7-fold higher
Acute myocardial infarction [13] 336 > 11.1 40% versus about 10%
Cerebrovascular accident [19] > 2000 ≥6.1–7 RR 3-fold higher
Cerebrovascular accident [18] 656 > 7.2 18% versus 11%
Severe brain damage [39] 59 > 11.1 Higher mortality
BG, blood glucose; RR, relative risk.
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hyperglycaemia (BG > 7.5 mmol/l) were independent predic-
tors of mortality, infection, and hospital and ICU length of
stay. Sung and coworkers [20] stratified 1003 consecutive
trauma patients by admission glucose level (<11.1 mmol/l
versus ≥11.1 mmol/l) and found a 2.2 times greater mortality
risk in the hyperglycaemic group. In a retrospective study
conducted in 865 trauma and 5234 nontrauma patients
(mortality in both groups 12%) [21], the relation between
hyperglycaemia and mortality was stronger in trauma patients
than in other surgical ICU patients.
Summary
The prevalence of hyperglycaemia in critically ill patients
approaches 100%. For the majority of studies, a negative
correlation between hyperglycaemia and survival was
demonstrated.
Can tight glucose control affect outcome in
critically ill patients?
To date, only a few studies that reached their goal for TGC
have been reported [7,22,23]; the results of ongoing
multicentre studies (Normoglycaemia in Intensive Care
Evaluation and Survival Using Glucose Algorithm Regulation
[NICE-SUGAR] and Comparing the Effects of Two Glucose
Control Regimens by Insulin in Intensive Care Unit Patients
[GLUCONTROL]) will be available in due course. Reviews
comparing the results of glucose regulation studies in
critically ill patients expose important drawbacks; the
(various) targets appear difficult to achieve, blood glucose
determinations are not standardized and the number of
patients is often limited [3,24]. Furthermore, perioperative
studies aiming to achieve better glucose control and studies
conducted in patients with AMI generally have a very limited
period of observation [24]. In most studies conducted before
2001 normoglycaemia was not a goal; this changed following
the impressive results reported in thoracosurgical ICU
patients by van den Berghe and coworkers in 2001 [7].
Glycaemic goals became tighter, with a target range between
4 and 8 mmol/l.
Intensive care unit patients
In a prospective randomized single centre study conducted in
765 cardiosurgical ICU patients, van den Berghe and
coworkers [7] showed that TGC decreased mortality and
morbidity substantially. Mean morning BG was
5.7 ± 1.1 mmol/l; 5.1% of patients had hypoglycaemic
episodes (< 2.2 mmol/l). Krinsley [23] found a beneficial
effect of glucose regulation (mean BG 7.2 mmol/l; <1%
hypoglycaemic episodes) on mortality, using a historical
control group. However, in a recent prospective study
conducted in a medical ICU population, van den Berghe and
coworkers [22] found that reduced BG levels did not
significantly reduce in-hospital mortality (40%) for the group
as a whole but just for the subgroup of patients with an ICU
stay of 3 or more days. Furthermore, TGC appeared to be
more difficult to achieve in medical ICU patients, among other
patients, resulting in an increase in hypoglycaemic events. In
that study, the potential benefit of glucose regulation may be
small because of the high mortality caused by the underlying
diseases (malignancy, chronic obstructive pulmonary disease,
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Figure 1
Survival by blood glucose level. Shown are Kaplan-Meier survival curves
for patients without known diabetes mellitus and admission blood
glucose levels less than 141 mg/dl (7.8 mmol/l; group 1),
141–199 mg/dl (7.8–11.0 mmol/l; group 2) and 200.0 mg/dl
(11.1 mmol/l) or higher (group 3), and patients with previously diagnosed
with diabetes (group 4). Adapted from Stranders and coworkers [16].
Figure 2
Relationship between mean blood glucose during ICU stay and ICU
mortality. Blood glucose levels are given in mmol/l. Data are from 1085
consecutive mixed ICU patients [4]. ICU, intensive care unit.
heart failure) and as a result of ‘dilution’ of the study with
patients whose conditions were not relevant to the study
goals. The number needed to treat to prevent an ICU death
and the associated risk for hypoglycaemia (number needed to
harm) with TGC may vary widely according to baseline
mortality, case mix and case selection [9].
Patients with acute myocardial infarction
In an overview of nine studies of glucose–insulin–potassium
(GIK) infusion conducted in patients with AMI (n = 932) [25],
treatment was associated with a decrease in 30-day mortality
from 21% to 16.1% (P = 0.004). In four ‘high-dose’ GIK
studies (288 patients), differences in mortality were not
statistically significant. In the DIGAMI study (n = 620) [26],
an absolute reduction in mortality of 7.5% was achieved. The
more recent DIGAMI 2 trial [17] did not support the evidence
that an acutely introduced, long-term insulin regimen
improves survival or lowers the number of reinfarctions in
patients with type 2 diabetes following AMI. In that study, only
one out of five patients was treated with coronary artery
bypass grafting or primary percutaneous coronary inter-
vention. Several other studies using GIK infusion failed to
demonstrate a beneficial effect on mortality: the ECLA
(Estudios Cardiologicos Latinoamerica) study (n = 490) [27],
the Pol-GIK (Polish-Glucose-Insulin-Potassium) trial (n = 954)
[28], the GIPS (Glucose-Insulin-Potassium Study) study [29]
(n = 940), the REVIVAL (Reevaluation of Intensified Venous
Metabolic Support for Acute Infarct Size Limitation) trial
(n = 312) [30], and the CREATE-ECLA (Clinical Trial of
Metabolic Modulation in Acute Myocardial Infarction-ECLA)
trial (n = > 20,000) [31].
Most studies performed with GIK infusion protocols were
originally not designed to achieve TGC; they do not result in
adequate glucose regulation and may in some patients have
unfavourable side effects. A recent report [32] suggests that
GIK infusion, despite high insulin infusion rates, may cause
refractory hyperglycaemia, which appeared to be an indepen-
dent parameter for larger myocardial infarction. Optimal
reperfusion therapy appears to be much more important for
AMI patients.
Cardiac surgery patients
During cardiac surgery glucose regulation results in a reduction
in complications, but an effect on mortality has not been
demonstrated. It was shown that arrhythmias were less
frequent, resulting in a shorter hospital stay [33,34]. In a
recently published trial conducted in 1127 high-risk patients
undergoing coronary artery bypass grafting, the addition of
10 IU/l insulin to the GIK infusion did not yield any benefit; even
in this high-risk group the perioperative mortality was only 2.2%
[35]. There are various reasons why a favourable effect of GIK
on mortality during cardiac surgery has not been shown: the
low mortality risk in these patients requires a large study
population, the optimal dose to be administered is unknown,
and different studies describe different patient populations.
Patients with cerebrovascular accident
In the GIST (Glucose Insulin in Stroke Trial) study [36], GIK
infusion in 53 hyperglycaemic patients with CVA did not
result in lower BG values and did not reduce short-term
mortality (32% versus 28%; not significant).
Summary
Taken together, most recent trials aiming to achieve TGC,
there appears to be a tendency toward a favourable effect of
glucose regulation in ICU patients. In AMI and CVA patients
no such effect has yet been demonstrated.
To be able to judge and compare future studies, strict
definitions of hyperglycaemia (and consequently of normo-
glycaemia and hypoglycaemia) and of patient populations are
needed. It would be feasible to define hyperglycaemia as any
blood glucose value above 6.1 mmol/l measured in whole
blood (or > 7.0 mmol/l measured in plasma), which is similar
to the World Health Association and American Diabetes
Association criteria [37].
Conclusion
The prevalence of hyperglycaemia in critically ill patients is
considerable; using stringent criteria it approaches 100%. An
clear negative correlation of hyperglycaemia with survival has
been shown. It is therefore likely that there is a pathophysio-
logical link between acute hyperglycaemia and complications/
mortality. The underlying mechanisms may differ considerably
in various situations of stress and various clinical conditions.
Whether hyperglycaemia is an independent risk factor in
critically ill patients can only be demonstrated in outcome
trials involving TGC. No evidence of a favourable effect of
TGC has yet been reported for patients with AMI and CVA. In
ICU patients the findings remain unclear, although there is a
tendency toward a favourable effect. Multicentre trials are
underway and their findings will hopefully shed more light on
this issue.
Competing interests
The authors declare that they have no competing interests.
Acknowledgements
We thank Joline Lind, MD, for language editing.
References
1. Lind L, Lithell H: Impaired glucose and lipid metabolism seen
in intensive care patients is related to severity of illness and
survival. Clin Intensive Care 1994, 5:100-105.
2. Yendamuri S, Fulda GJ, Tinkoff GH: Admission hyperglycemia
as a prognostic indicator in trauma. J Trauma 2003, 55:33-38.
3. Pittas AG, Siegel RD, Lau J: Insulin therapy for critically ill hos-
pitalized patients: a meta-analysis of randomized controlled
trials. Arch Intern Med 2004, 164:2005-2011.
4. Ligtenberg JJ, Meijering S, Stienstra Y, Horst ICC, Vogelzang M,
Nijsten MW, Tulleken JE, Zijlstra JG: Mean glucose level is not
an independent risk factor for mortality in mixed ICU patients.
Intensive Care Med. 2006, 32:435-438.
5. Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi
AE: Hyperglycemia: an independent marker of in-hospital
mortality in patients with undiagnosed diabetes. J Clin
Endocrinol Metab 2002, 87:978-982.
Critical Care    Vol 10 No 3 Corstjens et al.
Page 4 of 5
(page number not for citation purposes)
6. Cely CM, Arora P, Quartin AA, Kett DH, Schein RM: Relationship
of baseline glucose homeostasis to hyperglycemia during
medical critical illness. Chest 2004, 126:879-887.
7. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyn-
inckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouil-
lon R: Intensive insulin therapy in critically ill patients. N Engl J
Med 2001, 345:1359-1367.
8. Freire AX, Bridges L, Umpierrez GE, Kuhl D, Kitabchi AE: Admis-
sion hyperglycemia and other risk factors as predictors of
hospital mortality in a medical ICU population. Chest 2005,
128:3109-3116.
9. Egi M, Bellomo R, Stachowski E, French CJ, Hart G, Stow P, Li
W, Bates S: Intensive insulin therapy in postoperative inten-
sive care unit patients: a decision analysis. Am J Respir Crit
Care Med 2006, 173:407-413.
10. Christiansen C, Toft P, Jorgensen HS, Andersen SK, Tonnesen E:
Hyperglycaemia and mortality in critically ill patients. A
prospective study. Intensive Care Med 2004, 30:1685-1688.
11. Whitcomb BW, Pradhan EK, Pittas AG, Roghmann MC, Perence-
vich EN: Impact of admission hyperglycemia on hospital mor-
tality in various intensive care unit populations. Crit Care Med
2005, 33:2772-2777.
12. Krinsley JS: Association between hyperglycemia and
increased hospital mortality in a heterogeneous population of
critically ill patients. Mayo Clin Proc 2003, 78:1471-1478.
13. Bolk J, van der Ploeg T, Cornel JH, Arnold AE, Sepers J, Umans
VA: Impaired glucose metabolism predicts mortality after a
myocardial infarction. Int J Cardiol 2001, 79:207-214.
14. Tenerz A, Lonnberg I, Berne C, Nilsson G, Leppert J: Myocardial
infarction and prevalence of diabetes mellitus. Is increased
casual blood glucose at admission a reliable criterion for the
diagnosis of diabetes? Eur Heart J 2001, 22:1102-1110.
15. Capes SE, Hunt D, Malmberg K, Gerstein HC: Stress hypergly-
caemia and increased risk of death after myocardial infarction
in patients with and without diabetes: a systematic overview.
Lancet 2000, 355:773-778.
16. Stranders I, Diamant M, van Gelder RE, Spruijt HJ, Twisk JW,
Heine RJ, Visser FC: Admission blood glucose level as risk
indicator of death after myocardial infarction in patients with
and without diabetes mellitus. Arch Intern Med 2004, 164:982-
988.
17. Malmberg K, Ryden L, Wedel H, Birkeland K, Bootsma A, Dick-
stein K, Efendic S, Fisher M, Hamsten A, Herlitz J, et al.: Intense
metabolic control by means of insulin in patients with dia-
betes mellitus and acute myocardial infarction (DIGAMI 2):
effects on mortality and morbidity. Eur Heart J 2005, 26:650-
661.
18. Williams LS, Rotich J, Qi R, Fineberg N, Espay A, Bruno A,
Fineberg SE, Tierney WR: Effects of admission hyperglycemia
on mortality and costs in acute ischemic stroke. Neurology
2002, 59:67-71.
19. Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein HC: Stress
hyperglycemia and prognosis of stroke in nondiabetic and
diabetic patients: a systematic overview. Stroke 2001, 32:
2426-2432.
20. Sung J, Bochicchio GV, Joshi M, Bochicchio K, Tracy K, Scalea
TM: Admission hyperglycemia is predictive of outcome in crit-
ically ill trauma patients. JTrauma 2005, 59:80-83.
21. Vogelzang M, Nijboer JM, van der Horst IC, Zijlstra F, ten Duis HJ,
Nijsten MW: Hyperglycemia has a stronger relation with
outcome in trauma patients than in other critically ill patients.
JTrauma 2006, 60:873-877.
22. Van Den Berghe G., Wilmer A, Hermans G, Meersseman G,
Wouters P, Milants I, Van Wijngaarden E, Bobbaers H, Bouillon R:
Intensive Insulin therapy in the medical ICU. N Engl J Med
2006, 354:449-461.
23. Krinsley JS: Effect of an intensive glucose management proto-
col on the mortality of critically ill adult patients. Mayo Clin
Proc 2004, 79:992-1000.
24. Meijering S, Corstjens AM, Tulleken JE, Meertens JHJ, Zijlstra JG,
Ligtenberg JJ: Towards a feasible algorithm for tight glycaemic
control in critically ill patients: a systemic review of the litera-
ture. Crit Care 2006, 10:R19.
25. Fath-Ordoubadi F, Beatt KJ: Glucose-insulin-potassium therapy
for treatment of acute myocardial infarction: an overview of
randomized placebo-controlled trials. Circulation 1997, 96:
1152-1156.
26. Malmberg KA, Efendic S, Ryden LE: Feasibility of insulin-
glucose infusion in diabetic patients with acute myocardial
infarction. A report from the multicenter trial: DIGAMI. Dia-
betes Care 1994, 17:1007-1014.
27. Diaz R, Paolasso EA, Piegas LS, Tajer CD, Moreno MG, Corvalan
R, Isea JE, Romero G: Metabolic modulation of acute myocar-
dial infarction. The ECLA (Estudios Cardiologicos Latinoamer-
ica) Collaborative Group. Circulation 1998, 98:2227-2234.
28. Ceremuzynski L, Budaj A, Czepiel A, Burzykowski T, Achremczyk
P, Smielak-Korombel W, Maciejewicz J, Dziubinska J, Nartowicz E,
Kawka-Urbanek T, et al.: Low-dose glucose-insulin-potassium
is ineffective in acute myocardial infarction: results of a ran-
domized multicenter Pol-GIK trial. Cardiovasc Drugs Ther
1999, 13:191-200.
29. van der Horst IC, Zijlstra F, van’t Hof AW, Doggen CJ, de Boer
MJ, Suryapranata H, Hoorntje JC, Dambrink JH, Gans RO, Bilo
HJ: Glucose-insulin-potassium infusion inpatients treated
with primary angioplasty for acute myocardial infarction: the
glucose-insulin-potassium study: a randomized trial. J Am
Coll Cardiol 2003, 42:784-791.
30. Pache J, Kastrati A, Mehilli J, Bollwein H, Ndrepepa G, Schuhlen
H, Martinoff S, Seyfarth M, Nekolla S, Dirschinger J, et al.: A ran-
domized evaluation of the effects of glucose-insulin-potas-
sium infusion on myocardial salvage in patients with acute
myocardial infarction treated with reperfusion therapy. Am
Heart J 2004, 148:e3.
31. Mehta SR, Yusuf S, Diaz R, Zhu J, Pais P, Xavier D, Paolasso E,
Ahmed R, Xie C, Kazmi K, et al.: Effect of glucose-insulin-potas-
sium infusion on mortality in patients with acute ST-segment
elevation myocardial infarction: the CREATE-ECLA random-
ized controlled trial. JAMA 2005, 293:437-446.
32. Vogelzang M, Svilaas T, van der Horst IC, Nijsten MW, Zijlstra F:
Refractory hyperglycaemia induced by glucose-insulin-potas-
sium infusion in acute myocardial infarction. Neth Heart J
2006, 14:46-48.
33. Lazar HL, Chipkin S, Philippides G, Bao Y, Apstein C: Glucose-
insulin-potassium solutions improve outcomes in diabetics
who have coronary artery operations. Ann Thorac Surg 2000,
70:145-150.
34. Lazar HL, Chipkin SR, Fitzgerald CA, Bao Y, Cabral H, Apstein
CS: Tight glycemic control in diabetic coronary artery bypass
graft patients improves perioperative outcomes and
decreases recurrent ischemic events. Circulation 2004, 109:
1497-1502.
35. Rao V, Christakis GT, Weisel RD, Ivanov J, Borger MA, Cohen G:
The insulin cardioplegia trial: myocardial protection for urgent
coronary artery bypass grafting. J Thorac Cardiovasc Surg
2002, 123:928-935.
36. Scott JF, Robinson GM, French JM, O’Connell JE, Alberti KG,
Gray CS: Glucose potassium insulin infusions in the treat-
ment of acute stroke patients with mild to moderate hyper-
glycemia: the Glucose Insulin in Stroke Trial (GIST). Stroke
1999, 30:793-799.
37. Alberti KG, Zimmet PZ: Definition, diagnosis and classification
of diabetes mellitus and its complications. Part 1: diagnosis
and classification of diabetes mellitus provisional report of a
WHO consultation. Diabet Med 1998, 15:539-553.
38. Gore DC, Chinkes D, Heggers J, Herndon DN, Wolf SE, Desai M:
Association of hyperglycemia with increased mortality after
severe burn injury. J Trauma 2001, 51:540-544.
39. Young B, Ott L, Dempsey R, Haack D, Tibbs P: Relationship
between admission hyperglycemia and neurologic outcome
of severely brain-injured patients. Ann Surg 1989, 210:466-
472.
Available online http://ccforum.com/content/10/3/216
Page 5 of 5
(page number not for citation purposes)
